Cited by 710Cancer-related Molecular PathwaysHeat shock proteins researchCell death mechanisms and regulation

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Tovar, Christian, Rosinski, James, Filipovic, Zoran, Higgins, Brian, Kolinsky, Kenneth, Hilton, Holly, Zhao, Xiaolan, Vu, Binh T., Qing, Weiguo, Packman, Kathryn, Myklebost, Ola, Heimbrook, David C., Vassilev, Lyubomir T.·2006·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0507493103

Open this paper in CoChat — free account

Abstract

The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved in multiple tumor-derived cell lines expressing wild-type p53, but many have a reduced ability to undergo p53-dependent apoptosis. Gene array analysis revealed attenuated expression of multiple apoptosis-related genes. Cancer cells with mdm2 gene amplification were most sensitive to nutlin-3 in vitro and in vivo , suggesting that MDM2 overexpression may be the only abnormality in the p53 pathway of these cells. Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53–MDM2 interaction.

Integrity signals

Registry

Crossref · 10.1073/pnas.0507493103

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citation
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967

Show all 36 references

Research works printed but not linked: 4

K. H. Vousden, C. Prives Cell 120, 7–10 (2005).
D. P. Steensma, M. Timm, T. E. Witzig Methods Mol. Med 85, 323–332 (2003).
K. Satyamoorthy, N. H. Chehab, M. J. Waterman, M. C. Lien, W. S. El-Deiry, M. Herlyn, T. D. Halazonetis Cell Growth Differ 11, 467–474 (2000).
H. Yang, Z. Filipovic, D. Brown, S. N. Breit, L. T. Vassilev Mol. Cancer Ther 2, 1023–1029 (2003).

Sorted by citations

Items 601–700 of 710

CURRENT IMPLICATIONS FOR CANCER DETECTION, PREVENTION, AND THERAPEUTICS*
Krueger, K. E., & Srivastava, S. (2006) · Cited by 1
Senescence, Apoptosis, and Cancer
Dimri, M., & Dimri, G. P. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_10 · Cited by 1
Proteomic screening identifies PML/p53 axis as a potential treatment target of facial nerve schwannomas.
Wang, Z., Chen, H., Xue, L., He, W., Jiang, L., Wang, Z., & Wu, H. (2020) · PubMed Central · Cited by 1
Novel approaches to the treatment of high-grade sarcoma
Müller, C. R. (2011) · NORA - Norwegian Open Research Archives · Cited by 1
FLIP(L) determines p53 induced life or deathPreprint
Lees, A., McIntyre, A. J., Falcone, F., Crawford, N., McCann, C. K., Quinn, G. P., Roberts, J. Z., Sessler, T., Gallagher, P. F., Gregg, G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/858688 · Cited by 1
P53 is a direct regulator of the immune co-stimulatory molecule CD80Preprint
Alibo, E., Mollaoglu, G., Dhainaut, M., Zhao, R., Rose, S. A., Baccarini, A., Parsons, R. E., & Brown, B. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.24.445214 · Cited by 1
CNS Cancers
Graeme, R. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc223 · Cited by 1
p53 Directly Downregulates the Expression of CDC20 to Exert Anti-Tumor Activity in Mantle Cell LymphomaPreprint
Chen, Y., Yang, P., Wang, J., Zhu, M., Wang, Y., Gao, S., Zhang, W., Ke, X., & Jing, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4051472 · Cited by 1
A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivoPreprint
Diepstraten, S. T., Deng, Y., Potts, M. A., Heidersbach, A. J., Koenig, C., Dorighi, K. M., Tai, L., Kueh, A. J., Whelan, L., Chang, C. W. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.666069 · Cited by 1
F-box proteins, cell cycle and cancer
Kim, J. (2015) · Data Archiving and Networked Services (DANS)
Induction of cellular senescence as a novel therapeutic strategy for melanoma treatment
Zhang, G. (2012) · ScholarlyCommons (University of Pennsylvania)
Structural and functional interrogation of Anterior Gradient-2
Gray, T. A. (2013) · ERA
Small Molecules as Research Tools for Studying the Biology of the Tumour Suppressor p53
Spinnler, C. (2011) · Figshare
Expression levels of MDM2 and MDMX proteins and their associated effects on P53 in human liposarcomas
Touqan, N. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
p53 at a Glance: The Story so Far
Heetun, M., Haque, S., & Loizidou, M. (2009) · UCL Discovery (University College London)
Molecular mechanisms of growth suppression by pharmacologically activated p53
Hedström, E. (2009) · Figshare
To reactivate or not to reactivate : Control of KSHV lytic replication is essential for apoptosis in response to p53 restoration
Sarek, G. (2010) · Työväentutkimus Vuosikirja
Cancer gene discovery and immunosurveillance studies using Sleeping Beauty mouse models
Rogers, L. M. (2012) · doi:10.17077/etd.ixcxbg6p
Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction
Shangary, S. K., Bernard, D., & Wang, S. (2010) · Wiley eBooks · doi:10.1002/9780470972137.ch10
Mechanisms of p53-mediated intrinsic and extrinsic tumor suppression
Li, H. (2014) · Figshare
TARGETING THE MDM2-P53 AXIS FOR THE TREATMENT OF DEDIFFERENTIATED LIPOSARCOMA
Bill, K. (2014) · Digital Commons-TMC (Texas Medical Center)
Modulation of p53's transcriptional function by small molecules
Nikulenkov, F. (2011) · Figshare
PHARMACOLOGICAL TARGETING OF P53 PATHWAY ALTERATIONS IN TUMORS
Zhao, Y. (2010) · Figshare
Restoring p53 Function: Novel Anticancer Approaches for an Old Foe
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054787112010010
The effects of leptomycin B on HPV-infected cells
Jolly, C. (2008) · St Andrews Research Repository (St Andrews Research Repository)
Hemmung von Bcr/Abl durch Imatinib führt zu einer Cisplatin-Sensitivierung und zu einer modulierten p53-Funktion bei Bcr/Abl-positiven Zellen
Skorta, I. (2009) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-1857
Mutacje TP53 w nowotworach hematologicznych
Zajac, M., & Giannopoulos, K. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.11.005
The interaction of focal adhesion kinase with apoptotic regulators underpins anoikis resistance in human oesophageal carcinoma
Fanucchi, S. (2011) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial strategies
Vital, H. S. T. (2012)
Preclinical Pharmacology of the MDM2 Antagonist Nutlin-3a
Zhang, F. (2011) · doi:10.21007/etd.cghs.2011.0372
Mechanisms of p53-mediated Intrinsic and Extrinsic Tumor Suppression
Selivanova, G., Höglund, P., Piaggio, G., Elena, R., Pereira, T., Wright, A. R., Wadelius, C., & Universitit, U. (2014)
Controlling the intracellular processes
Puszyński, K., Jaksik, R., & Lalik, A. (2014) · IFAC Proceedings Volumes · doi:10.3182/20140824-6-za-1003.01201
Reactivation of the p53 pathway by MDM2 inhibitor Nutlin-3: Application in photochemical internalisation (PCI)
Lavoll, C. (2013) · NORA - Norwegian Open Research Archives
A Pilot Evaluation of p53 Activating Therapy as a Novel Strategy in the Treatment of Acute Myeloid Leukaemia
Venås, G. (2008) · NORA - Norwegian Open Research Archives
High dimensional data analysis for new insight in ovarian cancer phenotypes
Fehrmann, R. S. N. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Signaling Pathways Dynamics and Cancer Treatment
Świerniak, A., Kimmel, M., Śmieja, J., Puszyński, K., & Psiuk-Maksymowicz, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-28095-0_5
p53 Tumor Suppressor Opens Gateways for Cancer Therapy
Dai, M., Gallegos, J. R., & Lu, H. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch48
Exploring Chromatin-bound MDM2 Functions in Compromised Transcriptional Regulation of p53 Target Genes
Rosso, M. (2015) · CUNY Academic Works (City University of New York)
Geometry based general prediction model of protein-peptide binding affinities
Liu, Z., & Hu, J. (2016) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2016.7822757
Role of O6-methylguanine-DNA methyltransferase and p53 in response of neuroblastoma cells to an alkylating agent temozolomide
Рамисович, Х. Р., & Boychuk, S. V. (2018) · Kazan medical journal · doi:10.17816/kmj2018-047
Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure ProportionPreprint
Rufibach, K., Heinzmann, D., & Monnet, A. (2019) · arXiv (Cornell University)
Screening of p53-MDM2 interaction inhibitors through genome editing, high-content screening, and surface plasmon resonance
Taşkıran, H. (2018) · Sabanci University
In Vivo Discoveries in MDM2-Mediated p53 Regulation
Tackmann, N. R. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/z7ta-7m83
Characterization of synthetic lethality between Mdm2 overexpression and genotoxic agents and identification of a novel function of the Mdmx oncogene in DNA repair
Carrillo, A. M. (2014)
Discovery of AMG 232, a Small Molecule MDM2 Inhibitor in Clinical Development and its Back-up Clinical Candidate, AM-7209
Rew, Y., & Eksterowicz, J. E. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00280
Gene Expression-Based Prediction of Lung Cancer-Associated Protein-Protein Interactions
Dey, L., & Mukhopadhyay, A. (2021) · Communications in computer and information science · doi:10.1007/978-3-030-75529-4_17
Transcriptional burst kinetics are linked to short term transcriptional memoryPreprint
Senecal, A., Singer, R. H., & Coleman, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.31.466715
A Novel Intramolecular Interaction in P53
He, F. (2020) · Digital Commons - University of South Florida (University of South Florida)
Molecular Biology and Prostate Cancer
Shaw, G. L., & Neal, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_2
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
Ooi, M. G. M. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University)
Identification of ZER6 Isoform p52-ZER6 as an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding InhibitorsPreprint
Li, W., Alfason, L., Huang, C., Tang, Y. R., Li, Q., Miyagishi, M., Wu, S., & Kasim, V. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4003211
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7056
Characterization of consecutive p53 responses separated by a period of recovery in human cells and samples from acute myeloid leukemia patients undergoing allogenic stem cell transplantation
Chmara, J. (2016) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2016-11527
Faculty Opinions recommendation of Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy.
Narita, M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735976959.793564895
Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment
ElSawy, K. M., Alminderej, F. M., Verma, C. S., & Caves, L. S. D. (2022) · Molecular Systems Design & Engineering · doi:10.1039/d2me00042c
Data from Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma
Dewaele, B., Floris, G., Finalet-Ferreiro, J., Fletcher, C. D. �., Coindre, J., Guillou, L., Hogendoorn, P. C. W., Woźniak, A., Vanspauwen, V., Schöffski, P., et al. (2023) · doi:10.1158/0008-5472.c.6500213.v1
Data from Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2023) · doi:10.1158/0008-5472.c.6497172
Data from Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2023) · doi:10.1158/0008-5472.c.6497172.v1
Data from Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin
(2023) · doi:10.1158/0008-5472.c.6495480.v1
Self-citation
Data from Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin
(2023) · doi:10.1158/0008-5472.c.6495480
Self-citation
The effect of estradiol during the early stages of osteoclast differentiation is associated with the accumulation of phosphorylated p53 in mitochondria and the inhibition of mitochondrial metabolismPreprint
Marques-Carvalho, A., Silva, B., Pereira, F. B., Kim, H., Almeida, M., & Sardão, V. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.30.534893
Data from Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells
Moran, D. M., & Maki, C. G. (2023) · doi:10.1158/1535-7163.c.6532196.v1
Data from Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells
Moran, D. M., & Maki, C. G. (2023) · doi:10.1158/1535-7163.c.6532196
Supplementary Methods from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Tovar, C., Graves, B. J., Packman, K. E., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K. D., To, K.-H., et al. (2023) · doi:10.1158/0008-5472.22398767.v1
Self-citation
Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
Higgins, B. G., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K. D., Tannu, S. A., Adames, V., et al. (2023) · doi:10.1158/1078-0432.c.6523232
Self-citation
Supplementary Methods from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Tovar, C., Graves, B. J., Packman, K. E., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K. D., To, K.-H., et al. (2023) · doi:10.1158/0008-5472.22398767
Self-citation
Supplementary Figure 2 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.22522659.v1
Data from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.c.6543453.v1
Data from Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2023) · doi:10.1158/2326-6066.c.6550480.v1
A pipeline to characterize p53 effectors by integrative cistrome and transcriptome analysis in a genetically-defined organoid model
Shin, J.-H., Kim, H.-R., & Roe, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.03.009
Research progress in small-molecule modulators of protein-protein interactions
Yang, B., & Qi, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0034
Nutlin-3a induces KRAS mutant lung cancer specific methuosis-like cell death that is dependent on GFPT2Preprint
Kim, D., Min, D., Kim, J., Kim, J. M., Seo, Y., Jung, B. H., Kwon, S., & Lee, J.-Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.25.542296
Molecular genetics of soft tissue tumors
Lasota, J. P. (2016) · Cambridge University Press eBooks · doi:10.1017/9781107707504.006
Germ cell tumor treatment resistance and liquid biopsy-based microRNA biomarkers
Timmerman, D. M. (2024) · Utrecht University Repository (Utrecht University) · doi:10.33540/2055
A Review on Drug Design by the Application of Computer
Patil, N. S., Suryawanshi, H. S., Shaikh, A. Z., & Pawar, S. P. (2022) · Journal of Advanced Pharmaceutical Science and Technology · doi:10.14302/issn.2328-0182.japst-22-4363
Exploring the impact of p53 activation on spatio-temporal genome topology
Pasadas, M. C. (2024) · UPCommons institutional repository (Universitat Politècnica de Catalunya) · doi:10.5821/dissertation-2117-422069
In Silico Study of Pyrin and 14-3-3 Protein Modulation During FMF and PAAND
Paronyan, A., Muradyan, N., Sargsyan, A., Arakelov, V., Arakelov, G., & Nazaryan, K. (2025) · ACS Omega · doi:10.1021/acsomega.4c07386
Understanding Periodic Dynamics of P53-Mdm2 Interactions with the Stable Limit CyclesPreprint
Bani-Yaghoub, M., Menta, K., & Youan, B.-B. C. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5210081
β-catenin safeguards cell survival via a transcription-independent mechanism during the induction of primitive streak from hESCs
Zhang, P., Li, X., Bai, H., Zhao, Y., Rao, S.-L., He, L., Luo, X., & Yang, H. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02559-w
Molecular Glues as Activators for PPI
Qi, X. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch13
Language model encoded multi-scale feature fusion and transformation for predicting protein-peptide binding sites
Zhang, H., Chen, P., Yang, X., Wang, J., Shan, G., Chen, B. Y., & Jiang, B. (2025) · Pattern Recognition · doi:10.1016/j.patcog.2025.112487
Targeting the p53/MDM2 Pathway for Cancer Therapy
Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2
Self-citation
Molecular Therapy for Rhabdomyosarcoma
Kurmasheva, R. T., Hosoi, H., Kikuchi, K., & Houghton, P. J. (2010) · Springer eBooks · doi:10.1007/978-0-387-69062-9_20
Cellular Stress Responses to DNA Damage: An Intracellular Balance between Life, Senescence, and Death
Rommel, A., Goetz, E. M., Suzuki, M., Araki, S., Morales, J. C., Zou, Y. S., Luo, X., Boothman, D. A., Leskov, K., Matsuyama, S., et al. (2011) · Elsevier eBooks · doi:10.1016/b978-0-444-52272-6.00201-4
Additional file 1 of Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway
Wang, B., Gao, J., Zhao, Z., Zhong, X., Cui, H., Hou, H., Zhang, Y., Zheng, J., Di, J., & Liu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21062091
Additional file 2 of Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2
Kim, D., Min, D., Kim, J., Kim, M. J., Seo, Y., Jung, B. H., Kwon, S., Ro, H., Lee, S., Sa, J. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24804828
Additional file 1 of Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2
Kim, D., Min, D., Kim, J., Kim, M. J., Seo, Y., Jung, B. H., Kwon, S., Ro, H., Lee, S., Sa, J. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24804275
Analysis of the regulation of model parameters on delay time in the p53 dynamical response to single-stranded breaks
Ma, A., & Yang, X. (2026) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720026510017
Identification of MKRN1 as a key modulator of the p53-MDM2 feedback loop
Shimada, T., Noguchi, T., Komatsu, R., Otani, K., Komatsu, T., Suzuki, S., Mitsuya, M., Okubo, T., Ito, R., Yamada, M., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01662-4
Physiopathologie de l'hypertension artérielle pulmonaire : rôles de la voie de signalisation TGF-β/ALK1/Endogline et de p53
Gore, B. (2010) · theses.fr (ABES) · doi:10.70675/c07bbc56zd023z4202z8e97z7449d29922c5
Fonctions et régulations de la kinase CHK1 dans l'hématopoïèse normale et leucémique
Cartel, M. (2019) · theses.fr (ABES) · doi:10.70675/7824b06fz5467z4c2cz89c1zf5bed2a53f34
Implication des récepteurs à dépendance dans le processus tumoral : mécanismes et exploitation en thérapie anti-cancéreuse
Delloye‐Bourgeois, C. (2011) · theses.fr (ABES) · doi:10.70675/4113065azf844z4aceza648z1b5c64df1f33
Regulation of Netrin-1 by p53 isoforms
Sun, Y. (2020) · theses.fr (ABES) · doi:10.70675/814a2023zacd3z4475z897dz6ee94580c5a3
RING finger E3 ubiquitin ligases: novel therapeutic opportunities in melanoma
Zhang, J.-F., Li, L.-T., Yang, Y.-Y., Zhang, S.-C., Gao, C., Zhu, X., Xin, H., & Li, X. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00940-w
Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264
The advancement of Venetoclax in hematological malignancies and solid tumors
Long, C., Zhang, H., Yao, Y., Liu, T., Peng, H., & Sheng, Y. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45207
Targeting USP7 in sarcomas: opportunities and challenges
Franzese, S., & Cassinelli, G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118319
Hybrid AI-physics screening prioritizes candidate dual MDM2/MDM4 inhibitors from a drug-like library for dedifferentiated liposarcomaPreprint
Sackitey, S., Biniyam, P. D., Mireku, C. L., Hammah, A., Buabeng, J. A., Nkrumah, L. K., Asare, W. M., Oppong, J. F., Obeng, E. G., Adu-Adjei, K., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10832690/v1
A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo
Diepstraten, S. T., Deng, Y., Potts, M. A., Heidersbach, A. J., Koenig, C., Dorighi, K. M., Tai, L., Kueh, A. J., Whelan, L., Chang, C. W. T., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec0722 · Cited by 1
Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma
Boulouta, A., Digklia, A., Stergioula, A., & Kyriazoglou, A. I. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01414-z

Authors: Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D. C., & Vassilev, L. T.
Affiliations: *Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110; and
F. Hoffmann-La Roche AG (CH)
Institute for Cancer Research, Norwegian Radium Hospital, 0310 Oslo, Norway
ORCID: Higgins, Brian
Zhao, Xiaolan
Vu, Binh T.
Packman, Kathryn
Myklebost, Ola
Vassilev, Lyubomir T.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2006-01-27
Volume: 103
Issue: 6
Pages: 1888-1893
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0507493103
OpenAlex: W1993263392
Cited by: 708
References: 36
Citations by year: 2026: 17 · 2025: 24 · 2024: 15 · 2023: 39 · 2022: 23 · 2021: 27 · 2020: 25 · 2019: 33 · 2018: 20 · 2017: 27 · 2016: 44 · 2015: 39 · 2014: 45 · 2013: 39 · 2012: 47
FWCI: 25.66
Type: journal article
Language: en
Open access: closed
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: MDM2 inhibitors, Nutlin-3, p53 pathway, p53-dependent apoptosis, cell cycle arrest, MDM2 amplification, p53-MDM2 interaction, apoptosis-related gene expression, cancer therapy
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Cell Line, Humans, Imidazoles, Mice, Nude, Neoplasms, Piperazines, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Gene Expression Profiling, Xenograft Model Antitumor Assays, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks